Clinical trial
A Randomised, Double-blind, Single-centre, Placebo-controlled, First-in-human Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of CUR-N399 in Healthy Volunteers.
NCT05016687 is registered in ClinicalTrials.gov with Curovir AB as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomised, Double-blind, Single-centre, Placebo-controlled, First-in-human Clinical Trial Evaluating the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of CUR-N399 in Healthy Volunteers.
- Lead sponsor
- Curovir AB
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 22, 2021
- Completion date
- March 22, 2022
- Enrollment
- 74 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.